# PATENT

Docket No.: DEAV2003/0025 US NP

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Armin Hofmeister, et al.

Examiner:

Davis, Zinna Northington

Art Unit:

1625

Serial No.: 10/807,781

Filed:

March 24, 2004

Certificate of Transmission

Title:

Composition, Process of Making, and

Medical Use of Substituted 4-Phenyltetrahydroisoquinolines I hereby certify that this correspondence is being transmitted via EFS-Web to the Commissioner for Patents, Washington, D.C. 20231, on

June 1, 2006 Date of Transmission

Fier Pritchett Bein Pithth

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### Response to Restriction/Election Requirement Under 35 U.S.C. § 121

Sir:

This is in response to the Office Action, Paper No. 0506, dated, May 25, 2006, having a response due by June 25, 2006 in the above-identified patent application. It is respectfully requested that the following provisional election, and the remarks be entered in this case.

#### **PROVISIONAL ELECTION:**

Applicants provisionally elect with traverse the invention Group I, claims 1-6, 14 and 15 drawn to a chemical compound and a pharmaceutical composition of formula I.

## ELECTION OF A SUB-SPECIES AND A SINGLE DISCLOSED COMPOUND:

Applicants provisionally elect with traverse a sub-generic species falling within the scope of invention Group I to be a compound of formula I, wherein  $R_1 = R_3 = R_6 = R_7$ =  $R_8$  = hydrogen,  $R_2$  =  $R_4$  = halogen,  $R_5$  = alkyl,  $R_9$  = L-G, wherein L =  $NR_{30}CO$ -, and G  $= C_a(OR_{32})_x H_{2a+1-x}$ , wherein  $R_{30} = R_{32}$  = hydrogen and x = a = 5. A single specific compound falling within this sub-generic species is N-[3-(6,8-dichloro-2-methyl-1,2,3,4tetrahydroisoquinolin-4-yl)phenyl]-(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanamide, DEAV2003/0025 US NP -1 of 5-

Attorney Docket No.: DEAV2003/0025 US NP

Application No.: 10/807,781

Examiner: Davis, Zinna Northington

which is described as Example 2 at line 42, page 43 to line 22, page 44 of the specification. Please note that all of claims 1 to 6, 14 and 15 read on this elected subgeneric species as well as the single disclosed compound as provisionally elected herein.